Boule Diagnostics AB (CHIX:BOULS) Total Stockholders Equity: kr171.5 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:BOULS Boule Diagnostics AB CHIX:BOULS
47 GF Score
Price kr26.30
GF Value kr49.42
! 2 Warning Signs
View Full Analysis

What is Boule Diagnostics AB Total Stockholders Equity?

Boule Diagnostics AB CHIX:BOULS 47 Total Stockholders Equity is kr171.5 Mil as of Mar. 2026. GuruFocus rates CHIX:BOULS with a GF Score™ of 47/100 and a GF Value™ of kr49.42. The stock has 2 warning signs investors should review.

Boule Diagnostics AB's Total Stockholders Equity for the quarter that ended in Mar. 2026 was kr171.5 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Boule Diagnostics AB's Book Value per Share for the quarter that ended in Mar. 2026 was kr4.42. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Boule Diagnostics AB's Debt-to-Equity for the quarter that ended in Mar. 2026 was 1.29.

Boule Diagnostics AB  (CHIX:BOULs) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Boule Diagnostics AB's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(171.5-0)/38.833
=4.42

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Boule Diagnostics AB's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(134.2 + 87.8) / 171.5
=1.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boule Diagnostics AB Total Stockholders Equity Related Terms

Boule Diagnostics AB Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Boule Diagnostics AB's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Boule Diagnostics AB Total Stockholders Equity Chart

Boule Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 295.74 462.50 475.10 196.37 167.64

Boule Diagnostics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 172.90 161.50 168.40 167.64 171.50
CHIX:BOULS
47GF Score
Boule Diagnostics AB CHIX:BOULS
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of kr171.5 Mil mean?
Boule Diagnostics AB (CHIX:BOULS) has a Total Stockholders Equity of kr171.5 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Boule Diagnostics AB and its competitors.
Is Boule Diagnostics AB's Total Stockholders Equity too high?
Boule Diagnostics AB's current Total Stockholders Equity is kr171.5 Mil. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Total Stockholders Equity compare to ABT and SYK?
Boule Diagnostics AB's Total Stockholders Equity of kr171.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Boule Diagnostics AB and its competitors. Boule Diagnostics AB's current Total Stockholders Equity is kr171.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Total Stockholders Equity of kr171.5 Mil. The stock's GF Value™ is kr49.42, compared to a current price of kr26.30 — trading 46.8% below its estimated fair value. The current Total Stockholders Equity is kr171.5 Mil. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Total Stockholders Equity is kr171.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?

Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued. The current stock price of kr26.30 is trading 46.8% below its estimated GF Value™ of kr49.42.

Key valuation signals for CHIX:BOULS:

  • Total Stockholders Equity: kr171.5 Mil
  • GF Value™: kr49.42 vs. price of kr26.30 (46.8% below fair value)
  • GF Score™: 47/100 with 2 warning signs

No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Boule Diagnostics AB Business Description

Other Exchanges BOUL:Sweden
Address Fagerstagatan 7, Spanga, SWE, SE-163 53
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score

Get the complete analysis for CHIX:BOULS

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr26.30
Price
kr49.42
GF Value